VTVT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
-100.0%
36.8M
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
-100.0%
36.8M
0
0
0
Operating Expenses
13.9M
+2.6%
13.6M
+69.3%
8.0M
-25.0%
10.7M
+38.6%
7.7M
R&D
8.8M
-2.3%
9.0M
+129.7%
3.9M
-44.3%
7.0M
+71.1%
4.1M
SG&A
5.2M
+12.2%
4.6M
+15.6%
4.0M
+8.1%
3.7M
+1.7%
3.6M
Operating Income
-13930000
-159.9%
23.3M
+390.0%
-8021000
+25.0%
-10699000
-38.6%
-7721000
EBITDA
-13929000
-159.9%
23.3M
+390.1%
-8019000
+25.0%
-10697000
-38.6%
-7718000
Net Income
-13054000
-154.1%
24.1M
+438.1%
-7138000
+31.0%
-10345000
-40.2%
-7380000
EPS (Basic)
$-1.05
-154.1%
$1.94
+440.4%
$-0.57
+47.2%
$-1.08
-17.4%
$-0.92
EPS (Diluted)
$-1.05
-163.6%
$1.65
+389.5%
$-0.57
+47.2%
$-1.08
-17.4%
$-0.92
Shares (Diluted)
12.4M
-15.2%
14.6M
+17.4%
12.5M
+54.8%
8.1M
+22.3%
6.6M
vTv Therapeutics (VTVT) โ€” Financials